PLX
Protalix BioTherapeutics, Inc.
Price Chart
Latest Quote
$2.22
+0.20 (+9.90%)
Current Price
| Previous Close | $2.02 |
| Open | $2.04 |
| Day High | $2.23 |
| Day Low | $2.01 |
| Volume | 1,821,823 |
Stock Information
| Shares Outstanding | 80.57M |
| Total Debt | $8.48M |
| Cash Equivalents | $51.08M |
| Revenue | $76.38M |
| Net Income | $15.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $178.87M |
| P/E Ratio | 11.68 |
| EPS (TTM) | $0.19 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $136.27M |
| Sales | $76.38M |
| Income | $15.33M |
| Book/sh | $0.83 |
| Cash/sh | $0.63 |
| Employees | 226 |
Financial Ratios
| Quick Ratio | 1.97 |
| Current Ratio | 3.15 |
| Debt/Eq | 12.62 |
Returns & Margins
| ROA | 14.04% |
| ROE | 27.27% |
| Gross Margin | 45.24% |
| Operating Margin | 62.65% |
| Profit Margin | 20.07% |
Ownership
| Insider Ownership | 3.88% |
| Institutional Ownership | 21.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 3.58 |
| P/S | 2.34 |
| P/B | 2.66 |
Analyst Data
| Recommendation | none |
| Target Price | $11.00 |
Technical Indicators
| SMA20 | $2.05 |
| SMA50 | $2.09 |
| SMA200 | $2.18 |
| RSI | 58.21 |
| ATR | 0.0771 |
| Shares Float | 72.73M |
| Short Float | 5.08% |
| Short Ratio | 4.35 |
| Volatility | 0.01 |
| Rel Volume | 2.74 |
Performance History
| Week | +8.29% |
| Month | +16.84% |
| Quarter | -0.45% |
| 6 Months | +22.65% |
| YTD | +27.59% |
| Year | +62.04% |
| 3 Years | -3.06% |
| 5 Years | +2.30% |
| 10 Years | -71.17% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.22 | 1,832,900 |
| 2026-06-17 | $2.02 | 604,900 |
| 2026-06-16 | $2.06 | 228,200 |
| 2026-06-15 | $2.06 | 578,500 |
| 2026-06-12 | $2.09 | 255,000 |
| 2026-06-11 | $2.05 | 603,400 |
| 2026-06-10 | $1.97 | 360,800 |
| 2026-06-09 | $1.98 | 460,400 |
| 2026-06-08 | $1.96 | 454,700 |
| 2026-06-05 | $1.99 | 569,000 |
| 2026-06-04 | $2.01 | 597,100 |
| 2026-06-03 | $1.96 | 834,900 |
| 2026-06-02 | $1.99 | 810,200 |
| 2026-06-01 | $2.06 | 557,000 |
| 2026-05-29 | $2.11 | 487,900 |
| 2026-05-28 | $2.10 | 704,400 |
| 2026-05-27 | $2.12 | 1,120,000 |
| 2026-05-26 | $2.14 | 734,800 |
| 2026-05-22 | $2.10 | 714,000 |
| 2026-05-21 | $2.03 | 873,500 |
| 2026-05-20 | $2.01 | 702,600 |
| 2026-05-19 | $1.90 | 744,100 |
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; FundaçÃŖo Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
đ° Latest News
3 Penny Stocks With Market Caps Larger Than $100M To Consider
Simply Wall St. âĸ 2026-05-26T18:05:29Z
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T00:34:42Z
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
GuruFocus.com âĸ 2026-05-13T23:02:45ZTranscript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T12:19:50Z
April 2026 Penny Stocks With Promising Potential
Simply Wall St. âĸ 2026-04-10T18:05:08Z
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-18T19:00:32ZProtalix BioTherapeutics advances Fabry disease and gout programs during 2025
Proactive âĸ 2026-03-18T13:02:00Z
Protalix: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-18T11:06:49ZProtalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Proactive âĸ 2026-03-09T14:40:00Z
3 Promising Penny Stocks With Market Caps Up To $400M
Simply Wall St. âĸ 2026-02-09T18:05:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $26,993,000 | $24,319,000 | $22,982,000 | $19,592,000 |
| Cost Of Revenue | $26,993,000 | $24,319,000 | $22,982,000 | $19,592,000 |
| Total Revenue | $52,744,000 | $53,399,000 | $65,494,000 | $47,638,000 |
| Operating Revenue | $52,744,000 | $53,399,000 | $65,494,000 | $47,638,000 |
| Expenses | ||||
| Interest Expense | $1,191,000 | $1,062,000 | $3,180,000 | $2,529,000 |
| Total Expenses | $58,244,000 | $49,482,000 | $55,034,000 | $60,652,000 |
| Net Non Operating Interest Income Expense | $-108,000 | $237,000 | $-1,894,000 | $-1,383,000 |
| Interest Expense Non Operating | $1,191,000 | $1,062,000 | $3,180,000 | $2,529,000 |
| Operating Expense | $31,251,000 | $25,163,000 | $32,052,000 | $41,060,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Net Interest Income | $-108,000 | $237,000 | $-1,894,000 | $-1,383,000 |
| Interest Income | $1,083,000 | $1,299,000 | $1,286,000 | $1,146,000 |
| Normalized Income | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Net Income From Continuing And Discontinued Operation | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Total Operating Income As Reported | $-5,500,000 | $3,917,000 | $10,460,000 | $-13,014,000 |
| Net Income Common Stockholders | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Net Income | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Net Income Including Noncontrolling Interests | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Net Income Continuous Operations | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Pretax Income | $-5,608,000 | $4,154,000 | $8,566,000 | $-14,397,000 |
| Interest Income Non Operating | $1,083,000 | $1,299,000 | $1,286,000 | $1,146,000 |
| Operating Income | $-5,500,000 | $3,917,000 | $10,460,000 | $-13,014,000 |
| Gross Profit | $25,751,000 | $29,080,000 | $42,512,000 | $28,046,000 |
| Per Share | ||||
| Diluted EPS | $-0.08 | $0.04 | $0.09 | $-0.31 |
| Basic EPS | $-0.08 | $0.04 | $0.12 | $-0.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,952,000 | $6,520,000 | $12,937,000 | $-10,782,000 |
| Reconciled Depreciation | $1,465,000 | $1,304,000 | $1,191,000 | $1,086,000 |
| EBITDA (Bullshit earnings) | $-2,952,000 | $6,520,000 | $12,937,000 | $-10,782,000 |
| EBIT | $-4,417,000 | $5,216,000 | $11,746,000 | $-11,868,000 |
| Diluted Average Shares | $78,546,234 | $81,057,176 | $82,424,016 | $48,472,159 |
| Basic Average Shares | $78,546,234 | $72,530,698 | $67,512,527 | $48,472,159 |
| Diluted NI Availto Com Stockholders | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Tax Provision | $996,000 | $1,222,000 | $254,000 | $530,000 |
| Research And Development | $19,569,000 | $12,970,000 | $17,093,000 | $29,349,000 |
| Selling General And Administration | $11,682,000 | $12,193,000 | $14,959,000 | $11,711,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $48,230,000 | $43,211,000 | $33,569,000 | $-10,640,000 |
| Total Assets | $82,346,000 | $73,417,000 | $84,434,000 | $55,787,000 |
| Total Non Current Assets | $15,673,000 | $13,339,000 | $14,502,000 | $10,907,000 |
| Non Current Deferred Assets | $2,516,000 | $2,856,000 | $3,092,000 | $0 |
| Non Current Deferred Taxes Assets | $2,516,000 | $2,856,000 | $3,092,000 | $0 |
| Current Assets | $66,673,000 | $60,078,000 | $69,932,000 | $44,880,000 |
| Other Current Assets | $735,000 | $596,000 | $611,000 | $536,000 |
| Restricted Cash | $702,000 | $0 | - | - |
| Prepaid Assets | $394,000 | $500,000 | $444,000 | $774,000 |
| Inventory | $25,729,000 | $21,243,000 | $19,045,000 | $16,804,000 |
| Receivables | $8,840,000 | $2,909,000 | $5,272,000 | $4,586,000 |
| Accounts Receivable | $8,840,000 | $2,909,000 | $5,272,000 | $4,586,000 |
| Cash Cash Equivalents And Short Term Investments | $30,273,000 | $34,830,000 | $44,560,000 | $22,180,000 |
| Cash And Cash Equivalents | $14,680,000 | $19,760,000 | $23,634,000 | $17,111,000 |
| Debt | ||||
| Total Debt | $8,321,000 | $5,526,000 | $26,281,000 | $33,474,000 |
| Long Term Debt And Capital Lease Obligation | $6,937,000 | $4,026,000 | $4,621,000 | $32,356,000 |
| Current Debt And Capital Lease Obligation | $1,384,000 | $1,500,000 | $21,660,000 | $1,118,000 |
| Current Debt | - | - | $20,251,000 | - |
| Other Current Borrowings | - | - | $20,251,000 | - |
| Net Debt | - | - | - | $11,076,000 |
| Long Term Debt | - | - | - | $28,187,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,116,000 | $30,206,000 | $50,865,000 | $66,427,000 |
| Total Non Current Liabilities Net Minority Interest | $7,598,000 | $4,585,000 | $5,335,000 | $33,998,000 |
| Current Liabilities | $26,518,000 | $25,621,000 | $45,530,000 | $32,429,000 |
| Payables And Accrued Expenses | $22,825,000 | $22,310,000 | $22,265,000 | $16,729,000 |
| Payables | $11,037,000 | $11,145,000 | $7,833,000 | $7,173,000 |
| Other Payable | $2,828,000 | $3,136,000 | $637,000 | $781,000 |
| Total Tax Payable | $2,950,000 | $3,476,000 | $2,876,000 | $530,000 |
| Income Tax Payable | $2,950,000 | $3,476,000 | $2,876,000 | $530,000 |
| Accounts Payable | $5,259,000 | $4,533,000 | $4,320,000 | $5,862,000 |
| Interest Payable | - | $0 | $511,000 | $719,000 |
| Current Deferred Liabilities | - | - | $0 | $13,178,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $48,230,000 | $43,211,000 | $33,569,000 | $-10,640,000 |
| Total Equity Gross Minority Interest | $48,230,000 | $43,211,000 | $33,569,000 | $-10,640,000 |
| Stockholders Equity | $48,230,000 | $43,211,000 | $33,569,000 | $-10,640,000 |
| Retained Earnings | $-384,997,000 | $-378,393,000 | $-381,549,000 | $-389,861,000 |
| Other | ||||
| Ordinary Shares Number | $80,425,981 | $75,850,275 | $72,952,124 | $53,790,167 |
| Share Issued | $80,425,981 | $75,850,275 | $72,952,124 | $53,790,167 |
| Tangible Book Value | $48,230,000 | $43,211,000 | $33,569,000 | $-10,640,000 |
| Invested Capital | $48,230,000 | $43,211,000 | $53,820,000 | $17,547,000 |
| Working Capital | $40,155,000 | $34,457,000 | $24,402,000 | $12,451,000 |
| Capital Lease Obligations | $8,321,000 | $5,526,000 | $6,030,000 | $5,287,000 |
| Total Capitalization | $48,230,000 | $43,211,000 | $33,569,000 | $17,547,000 |
| Additional Paid In Capital | $433,147,000 | $421,528,000 | $415,045,000 | $379,167,000 |
| Capital Stock | $80,000 | $76,000 | $73,000 | $54,000 |
| Common Stock | $80,000 | $76,000 | $73,000 | $54,000 |
| Employee Benefits | $661,000 | $559,000 | $714,000 | $1,642,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $661,000 | $559,000 | $714,000 | $1,642,000 |
| Long Term Capital Lease Obligation | $6,937,000 | $4,026,000 | $4,621,000 | $4,169,000 |
| Current Capital Lease Obligation | $1,384,000 | $1,500,000 | $1,409,000 | $1,118,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,309,000 | $1,811,000 | $1,605,000 | $1,404,000 |
| Current Accrued Expenses | $11,788,000 | $11,165,000 | $14,432,000 | $9,556,000 |
| Defined Pension Benefit | $578,000 | $462,000 | $528,000 | $1,267,000 |
| Net PPE | $12,579,000 | $10,021,000 | $10,882,000 | $9,640,000 |
| Accumulated Depreciation | $-37,046,000 | $-35,739,000 | $-34,688,000 | $-33,686,000 |
| Gross PPE | $49,625,000 | $45,760,000 | $45,570,000 | $43,326,000 |
| Leases | $18,070,000 | $17,913,000 | $17,644,000 | $16,921,000 |
| Other Properties | $27,790,000 | $24,473,000 | $24,842,000 | $23,582,000 |
| Machinery Furniture Equipment | $3,765,000 | $3,374,000 | $3,084,000 | $2,823,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $10,374,000 | $5,449,000 | $5,814,000 | $10,618,000 |
| Work In Process | $9,375,000 | $11,245,000 | $9,055,000 | $2,678,000 |
| Raw Materials | $5,980,000 | $4,549,000 | $4,176,000 | $3,508,000 |
| Other Short Term Investments | $15,593,000 | $15,070,000 | $20,926,000 | $5,069,000 |
| Treasury Shares Number | - | - | $0 | - |
| Current Deferred Revenue | - | - | $0 | $13,178,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Current Provisions | - | - | - | $1,404,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,631,000 | $7,392,000 | $-2,467,000 | $-25,628,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-11,993,000 | $8,674,000 | $-1,318,000 | $-25,000,000 |
| Cash Flow From Continuing Operating Activities | $-11,993,000 | $8,674,000 | $-1,318,000 | $-25,000,000 |
| Operating Gains Losses | $2,000 | $-172,000 | $-38,000 | $-540,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,638,000 | $-1,282,000 | $-1,149,000 | $-628,000 |
| Investing Cash Flow | $-2,366,000 | $4,221,000 | $-16,711,000 | $-5,035,000 |
| Cash Flow From Continuing Investing Activities | $-2,366,000 | $4,221,000 | $-16,711,000 | $-5,035,000 |
| Net Other Investing Changes | $-728,000 | $80,000 | $-142,000 | $593,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $6,812,000 | $3,626,000 | $23,954,000 | $8,236,000 |
| Financing Cash Flow | $9,326,000 | $-16,794,000 | $24,666,000 | $8,238,000 |
| Cash Flow From Continuing Financing Activities | $9,326,000 | $-16,794,000 | $24,666,000 | $8,238,000 |
| Net Common Stock Issuance | $6,812,000 | $3,626,000 | $23,954,000 | $8,236,000 |
| Common Stock Issuance | $6,812,000 | $3,626,000 | $23,954,000 | $8,236,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-20,420,000 | $0 | $0 |
| End Cash Position | $14,680,000 | $19,760,000 | $23,634,000 | $17,111,000 |
| Beginning Cash Position | $19,760,000 | $23,634,000 | $17,111,000 | $38,985,000 |
| Effect Of Exchange Rate Changes | $-47,000 | $25,000 | $-114,000 | $-77,000 |
| Changes In Cash | $-5,033,000 | $-3,899,000 | $6,637,000 | $-21,797,000 |
| Proceeds From Stock Option Exercised | $2,514,000 | $0 | $712,000 | $2,000 |
| Net Issuance Payments Of Debt | $0 | $-20,420,000 | $0 | $0 |
| Net Short Term Debt Issuance | $0 | $-20,420,000 | $0 | $0 |
| Short Term Debt Payments | $0 | $-20,420,000 | $0 | $0 |
| Net Investment Purchase And Sale | $0 | $5,420,000 | $-15,420,000 | $-5,000,000 |
| Sale Of Investment | $5,000,000 | $20,420,000 | $5,000,000 | $11,000,000 |
| Purchase Of Investment | $-5,000,000 | $-15,000,000 | $-20,420,000 | $-16,000,000 |
| Net PPE Purchase And Sale | $-1,638,000 | $-1,279,000 | $-1,149,000 | $-628,000 |
| Sale Of PPE | $0 | $3,000 | $0 | $0 |
| Purchase Of PPE | $-1,638,000 | $-1,282,000 | $-1,149,000 | $-628,000 |
| Change In Working Capital | $-10,099,000 | $811,000 | $-10,539,000 | $-12,015,000 |
| Change In Other Current Assets | $-15,000 | $-4,000 | $13,000 | $-5,000 |
| Change In Payables And Accrued Expense | $292,000 | $696,000 | $5,295,000 | $-4,804,000 |
| Change In Inventory | $-4,486,000 | $-2,198,000 | $-2,241,000 | $1,150,000 |
| Change In Receivables | $-5,890,000 | $2,317,000 | $-428,000 | $-1,194,000 |
| Changes In Account Receivables | $-5,890,000 | $2,317,000 | $-428,000 | $-1,194,000 |
| Other Non Cash Items | $606,000 | $310,000 | $-600,000 | $-689,000 |
| Stock Based Compensation | $2,297,000 | $3,253,000 | $3,448,000 | $2,085,000 |
| Deferred Tax | $340,000 | $236,000 | $-3,092,000 | $0 |
| Deferred Income Tax | $340,000 | $236,000 | $-3,092,000 | $0 |
| Depreciation Amortization Depletion | $1,465,000 | $1,304,000 | $1,191,000 | $1,086,000 |
| Depreciation And Amortization | $1,465,000 | $1,304,000 | $1,191,000 | $1,086,000 |
| Depreciation | $1,465,000 | $1,304,000 | $1,191,000 | $1,086,000 |
| Pension And Employee Benefit Expense | $2,000 | $-169,000 | $-47,000 | $-540,000 |
| Gain Loss On Sale Of PPE | $0 | $-3,000 | $9,000 | $0 |
| Net Income From Continuing Operations | $-6,604,000 | $2,932,000 | $8,312,000 | $-14,927,000 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | $-13,178,000 | $-7,162,000 |
| Change In Other Current Liabilities | - | - | $0 | $0 |
| Interest Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-22